• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

TytoCare Receives CE Mark Approval for its Lung Sounds Analyzer

by Fred Pennic 02/15/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
COVID-19 Spikes Deaconess Health Adoption of Remote Medical Exams

What You Should Know:

– TytoCare has received CE Mark approval for its AI-backed Tyto Lung Sounds Analyzer, a web-based software system designed to aid in the clinical assessment of lung auscultation sound data by analyzing recorded lung sounds to determine whether wheezing is detected within the recording.

– The Lung Sounds Analyzer will further enable physicians to better diagnose respiratory conditions remotely. The CE Mark paves the way for the immediate European rollout of TytoCare’s Lung Sounds Analyzer Software that processes recordings from the CE marked and FDA-cleared off-the-shelf compatible electronic TytoCare Stethoscope. The company is currently seeking FDA clearance for the Lung Sounds Analyzer.

Lung Sounds Analyzer Background

TytoCare developed the Lung Sounds Analyzer based on its vast database of clinical exams. Analysis of this robust big data, in combination with clinical literature, fuels the decision support algorithms that powers the Lung Sounds Analyzer. The algorithms, which required testing on the large number of exam recordings unique to TytoCare, are uniquely equipped to handle lower quality data collected during user intake exams and to remove any interfering sounds. The company also worked with experienced pulmonologists and general practitioners to develop the analyzer. 

“Receiving the CE Mark on the Lung Sounds Analyzer is an important milestone for TytoCare, as it brings to market a powerful, highly integrated, and easy-to-use software system that will benefit both healthcare providers and patients,” said Dedi Gilad, CEO and co-founder of TytoCare. “We are confident that this will enhance telehealth usage in the European market and will help deliver improved outcomes in detecting wheezes, and in the future other respiratory abnormalities. In addition, this approval is a crucial step in our support of our European partners in their goal of transforming primary care delivery.”

TytoCare’s CE Mark approved and FDA-cleared handheld examination kit enables users to perform comprehensive physical exams of the heart, skin, ears, throat, abdomen, and lungs, and measure heart rate, body temperature, and blood oxygen levels which are key for treating many acute and chronic conditions. This allows health care clinicians to gain the vital clinical data they require to monitor, diagnose, and treat patients and avoid unnecessary in-person visits. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, lung, TytoCare

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |